Improvements in gait deficits with peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study
Objective: Quantify changes in gait parameters in patients with Parkinson’s disease (PD) who underwent autologous peripheral nerve grafts implantation (surgical deployment of the Schwann cells…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care
Objective: To demonstrate the adverse impact of non-medical switching on patient care. Background: Non-medical switching (NMS) is a policy under which insurers or their pharmacy…Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease
Objective: To evaluate the pharmacokinetics and pharmacodynamics of opicapone in Parkinson’s disease (PD). Background: Opicapone, a highly selective COMT inhibitor, is approved in Europe and…Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor
Objective: To examine use of γ-aminobutyric acid (GABA) type A receptor (GABA-A-R) positive allosteric modulators (PAMs) in the treatment of essential tremor (ET) in early…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens
Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE
Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…Two novel ANO10 mutations causing adult-onset autosomal recessive spinocerebellar ataxia
Objective: Clinical and genetic characterization of a patient Background: In recent years mutations more than 100 different genes have been shown to underlie spinocerebellar ataxias.…
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 217
- Next Page »